Nesta área tem acesso aos eventos nacionais e internacionais que dizem respeito à área da Hematologia. Pode optar por visualizar a Agenda por dia, mês ou semana. Pode clicar em “Ler mais” e encontrar informação mais detalhada.
The Francis Crick Institute – London, United Kingdom
Chairs: Michael Andreeff, Dominique Bonnet, Daniela S. Krause, Simon Méndez-Ferrer
Programme description:
This workshop offers highest level science on the nature of the normal and malignant haemopoietic stem cell niche. It also aims to present strategies to target haematological cancers in their tumour microenvironment, thereby combining basic research efforts with possible clinical applications. It is designed to promote scientific interaction between participants from all over the world, involving junior and senior biologists and clinicians working in both the academic and industrial settings.
Programa aqui
Abstract submission
Learning objectives:
- Define the currently known complexities of the normal and malignant haematopoietic stem cell niche
- Define the complexities of metabolic changes in the bone marrow microenvironment in health and disease
- Define the effects of inflammatory processes on the bone marrow microenvironment in health and disease
- Define the interaction of haematological cancer cells with their microenvironment and methods to visualize and mimic these
- Define strategies to target the malignant haematopoietic stem cell niche to augment existing therapies
Clinical Updates on CML/MPN
March 8-10, 2019
Saggart (Dublin), Ireland
Chairs: Claire Harrison, Andreas Hochhaus, Ruben Mesa
ESH Clinical Updates are disease-specific meetings that address state-of-the-art diagnostic and clinical management.
They are based on the presentation and analysis of real clinical cases. Voting technology is used as a self-evaluation tool and to increase scientific interaction.
This programme will include:
– Plenary Sessions
– Interactive Cases Presentations
– Roundtables
– Panel Discussions
– Debates
– Voting boxes
Consulte o programa aqui
Deadline For Clinical Cases And Abstracts Poster Presentation: JANUARY 6TH, 2019
Please send your clinical case in a .doc format to the following email address:
pauline.jaillard@univ-paris-diderot.fr and ghyslaine.lebougault@univ-paris-diderot.fr
Check that you do receive an acknowledgement of your submitted clinical case. If not, contact pauline.jaillard@univ-paris-diderot.fr
Please find below the clinical cases guidelines:
- Your clinical case can be structured (eg Objectives, Methods, Results, Conclusions) or unstructured
- Maximum number of words: 400
- Your clinical case will be submitted to the peer review procedure
- Your clinical case must be sent by email in a .doc format
- Your clinical case should contain the following information:1. Title (capital letters)
2. Authors with name of presenting author under-scored
3. Name and e-mail of corresponding author
4. Institution and city of origin
5. Text
6. Acknowledgements (if necessary) (no references please)
Erythropoiesis Control and Ineffective Erythropoiesis: from Bench to Bedside
Chairs: Maria Domenica Cappellini (Milan), Stuart Orkin (Boston), Valeria Santini (Florence)
March 15-17, 2019 – Budapest, Hungary
A. Programme description
The conference on erythropoiesis control and ineffective erythropoiesis which will be held in Budapest in March 2019, as the title underlines “from bench to bedside” has the main objective of translating the most recent basic science acquisitions related to the origin and the developmental control of mega/erythroid progenitors in haematopoiesis to clinical practice. Erythropoiesis is a complex multistep process going from committed erythroid progenitors to mature red cells, involving a talk to talk process with other haematopoietic progenitors. Although some recent advances allow the characterization of some components of erythropoiesis, much still remains to be investigated particularly on pathological erythropoiesis and in any haematological condition characterized by ineffective erythropoiesis. During erythropoiesis efficient cytoprotective systems, are required to limit possible ROS-related toxic effects: these systems play an even more important role in conditions of ineffective erythropoiesis (IE), such as thalassaemias, sickle cell disease and congenital dyserythropoietic anaemias (CDAs) but also in myelodysplastic syndromes (MDS). Blood transfusion therapy or treatments with erythropoiesis stimulating agents (ESAs), such as recombinant EPO, are so far the frontline therapies for aneamia associated with ineffective erythropoiesis (IE). However, both treatments are not without risks, and in some cases they are not effective, therefore, there is a clinical need for novel agents supporting IE with different mechanism(s) of action from existing ESAs.
The two and half days program includes 9 sessions alternating basic science to clinical practice including specific diseases such as CDAs, thalassaemia, SCD, haemolytic anaemias and MDS. More specifically session one on erythropoiesis control will elucidate the role of transcription factors, the single cell gene expression in erythroid commitment/development and the proteolytic remodeling of red cell. Session 2 will focus on the weight of ineffective erythropoiesis in different diseases in determining the phenotype expression of the disease (i.e. thalassaemia, SCD, MDS). Session III will complete the insights of molecular causes of ineffective erythropoiesis. Session IV will be very interactive presenting cases characterized by the clinical consequences of IE. Session V is focused on hemoglobin switching that represents an ideal model for understanding different mechanisms of gene regulation especially the mechanisms of switch genes off and on. Session VI will be very clinical with practical advises to care emergency events in patients with different red cell disorders. The last 3 sessions are dedicated to the new therapeutic approaches either pharmacological or molecular to erythroid disorders mainly targeting IE. The speakers are eminent experts in their field, making the faculty very attractive.
Consulte o programa aqui
B. Learning objectives
1. To understand the mechanisms that control erythropoiesis in the context of hematopoiesis
2. To identify the different causes of ineffective erythropoiesis
3. To translate the basic information in clinical practice in order to understand the different phenotype expressions of diseases such as thalassaemias, SCD, haemolytic anaemias and MDS
4. To be updated on the development of new drugs targeting ineffective erythropoiesis and the state of the art in clinical setting
5. To acquire skills in diagnosis and treatment of erythropoietic abnormalities in different haematological disorders
C. Why the meeting will be valuable for participants?
The meeting will offer a unique opportunity to discuss basic science in a clinical contest which will be created by presenting challenging clinical cases. The meeting is structured with the specific aim to be translational “from bench to bedside” involving participants in alive discussion
D. Audience
This meeting will be of interest to:
– Doctoral students and resident still in-training
– Junior and senior biologists and clinicians (MD, PhD, MD-PhD)
– Fully trained, early career as well as senior biologists and clinicians including experts in the field
2nd How to Diagnose and Treat Multiple Myeloma
April 5-7, 2019 – Berlin, Germany
Chairs: Hermann Einsele, Irene Ghobrial, Sonja Zweegman
ESH Clinical Updates are disease-specific meetings that address state-of-the-art diagnostic and clinical management.
They are based on the presentation and analysis of real clinical cases. Voting technology is used as a self-evaluation tool and to increase scientific interaction.
This programme will include:
– Plenary Sessions
– Interactive Cases Presentations
– Roundtables
– Panel Discussions
– Debates
– Voting boxes
O Dia Mundial da Hemofilia celebra-se a 17 de abril. Esta data é também conhecida como Dia Mundial do Hemofílico e é assinalada desde 1989.
O dia 17 de abril foi escolhido para celebrar o Dia Mundial da Hemofilia por ser o aniversário de Frank Schnabel, o fundador da Federação Mundial do Hemofilia, uma organização sem fins lucrativos que atua em 113 países do mundo. O objetivo deste dia é consciencializar as populações para a hemofilia e para outras desordens sanguíneas.
A hemofilia é uma anomalia do sangue caracterizada por uma demora ou uma falta de coagulação, sendo que a menor ferida pode provocar uma grave hemorragia.
Esta é uma afeção hereditária, transmitida pelas mulheres, que ataca sobretudo os homens. A forma mais comum de desordem é a hemofilia A, presente em 1 de 5.000-10.000 nascimentos masculinos. Já a hemofilia B acontece em aproximadamente 1 de 20,000-34,000 nascimentos masculinos.
Em Portugal não existe um registo nacional sobre a hemofilia, estimando-se que exista um milhar de pessoas com esta doença.
Celebra-se, a 18 de Abril, o Dia Europeu dos Direitos dos Doentes.
Este dia nasceu com o intuito de garantir que sejam respeitados os valores fundamentais reconhecidos pela Carta Europeia dos Direitos dos Doentes.
Dentro do espaço europeu, independentemente dos meios financeiros e da nacionalidade, é imperioso garantir que os cidadãos possam aceder a serviços de saúde de qualidade, mesmo quando o tratamento não está disponível no seu país de origem ou quando tem mais qualidade noutro Estado Membro.
O reforço e o respeito pelos direitos dos doentes só serão efetivos com a cooperação e o empenho de todos os profissionais da área da saúde em cada país da União Europeia. Assim, é essencial aumentar a consciencialização sobre a importância dos direitos dos doentes, bem como as responsabilidades de todos para garantir a seu respeito.
Fonte: https://www.sns.gov.pt
International Conference on Acute Lymphoblastic Leukaemia
Berlin, Germany
May 17-19, 2019
Chairs: Jan Cools (Leuven), Hervé Dombret (Paris), Adele Fielding (London), Mark Litzow (Rochester)
Programme summary:
Major advances have been reached recently in the knowledge of acute lymphoblastic leukaemia (ALL), including the comprehensive description of B-cell precursor and T-cell ALL genomic landscapes, identi cation of new potentially druggable disease subsets and discovery of predisposing preleukemic events. During the same period of time, progresses have been accomplished in the management of children and adults with ALL, thanks to routine monitoring of measurable residual disease (MRD), administration of intensi ed risk-adapted chemotherapy, introduction of targeted therapies and antibodies, followed by the remarkable efficacy of antibody-drug conjugates (ADCs), bi specific T-cell engager antibodies (BiTEs) and manufactured chimeric antigen receptor (CAR) T-cells.
This intense research activity has made ALL a fascinating disease, allowing major improvements in patients’ outcome, while providing important proofs of concept for the treatment of cancer in general.
The 1st ESH Translational Conference on ALL is designed to provide time and multiple opportunities for discussions and interactions with internationally recognized physicians and scientists in the field.
Consulte aqui o programa provisório
Learning objectives:
- Learn how to optimally diagnose and classify ALL, by combining modern diagnosis algorithms and early MRD monitoring, to rapidly deliver the right treatment to the right patient
- Review the conventional therapeutic options, with a focus on the role of allogeneic haematopoietic stem cell transplantation
- Learn how to optimize the management of individual patients on the basis of individual drug metabolism, tolerance and toxicity
- Acquire improved knowledge of new emerging targeted or immunologic treatments and understand how they might be combined or even eventually replace current conventional treatment options
The programme will include:
- Plenary Sessions
- Introductory and Keynote Lectures
- Roundtables
- Panel Discussions
- Simultaneous Meet the Expert Sessions
- Manned Poster Session
ESH International Conference on Cellular Therapies: Focus on Immune Based Therapeutic Concepts
September 20-22, 2019
Mandelieu Conference Centre, Mandelieu, France
Chairs: Chiara Bonini, Carl June, Max Topp
The programme will include:
- Plenary Sessions
- Late Breaking Session
- Panel Discussions
- Simultaneous Meet the Expert Sessions
- Manned Poster Session
Topics:
- Updates in CAR T Cell therapy for B-Cell tumours
- CAR T Cell therapies for acute myeloid leukaemia and multiple myeloma
- Management of resistance and toxicity to CAR T Cells
- Bites and other engineered antibody therapies
- Cellular therapies for Infections
- Non-T Cell therapies (MSC, Gamma-Delta T-Cells, etc.)
- Immune therapy strategies for solid tumours
- Cellular therapies for GVHD (SC, Suicide Genes, etc.)
